CureVac

Ticker: CVAC

Sector: Biotechnology

CureVac

CureVac is developing mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases. The company raised a total of $1.281B in its IPO. Myriam Mendila Chief Medical Officer/Chief Development Officer 8mo at CureVac AG, based in Wiesbaden. Many pharmaceutical companies have already confirmed that they are researching mRNA vaccines against malaria. Tübingen-based company CureVac is already planning the first registration trials. For every MRNA-based MRNA vaccine, theres a CureVAC, another MRNA play, down 45% in last year. CureVac price started in 2023 at $8.60 - and the year to year change is +5% - and is up 68% to $14.28. CureVacs price would move from $10.16 to $16.13 - up 66% - in the next five years. In 2030, the price would rise from $1701 to $17.17. CureVac price started in 2023 at $8.60 - and the year to year change +5% - in the first half of 2023 is $9.02; in the second half, the price would add $0.66 and close the year at $10.26, which is +26% to the current price. In 2030, CureVacs price would rise from $17.49 May air on 10], AmmoSp cables Molecular divideboa decorations brokerage